January 5, 2026

Global Opportunities Trust to appoint Goodhart as discretionary investment manager

Global Opportunities Trust plc has announced plans to appoint Goodhart Partners as discretionary investment manager, subject to regulatory approval...

Volta Finance appoints BNP Paribas Asset Management Europe as investment manager

Volta Finance Limited has appointed BNP Paribas Asset Management Europe as its new investment manager, effective 31 December 2025, following the merger of AXA Investment Managers and BNP Paribas Asset..

Outlook for investing in China 2026

Dale Nicholls, portfolio manager of Fidelity China Special Situations, outlines his outlook for Chinese equities in 2026, highlighting policy stabilisation, structural innovation leadership, and selective opportunities in advanced manufacturing, automation,..

Global Opportunities Trust Appoints Juniper as an External AIFM

Goodhart Partners is set to become discretionary investment manager to Global Opportunities Trust plc, aiming to increase portfolio flexibility, risk management, and real return potential...

Real Estate Credit Investments: Why 95% of Investors Voted to Stay In While Rivals Wind Down (Video)

RECI is going against the tide — while many peers wind down, it secured 95% shareholder backing to continue. Ravi Stickney and Andreas Tautscher explain the strategic edge RECI holds..

Rhythm Pharmaceuticals, Inc. (RYTM): Analyst Consensus and Growth Potential Amidst a 32% Upside

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stands out in the biotechnology sector with its focus on rare neuroendocrine diseases. Known for its flagship product, IMCIVREE, designed to address genetic obesity disorders,..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Biotech Pioneer with a Mixed Valuation Outlook

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stands as a significant player in the biotechnology sector, focusing on pioneering treatments for rare genetic diseases. Headquartered in Cambridge, Massachusetts, Sarepta has carved a..

Inspire Medical Systems, Inc. (INSP): Investor Outlook with a 51.73% Potential Upside

Inspire Medical Systems, Inc. (NASDAQ: INSP), a trailblazer in the healthcare sector, particularly within the medical devices industry, has garnered significant attention for its innovative approach to treating obstructive sleep..

Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator with Nearly 100% Upside Potential

Vaxcyte, Inc. (NASDAQ: PCVX), a clinical-stage biotechnology company, has been making waves in the healthcare sector with its innovative approach to vaccine development. Focused on addressing bacterial infectious diseases, Vaxcyte’s..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a leading entity in the biotechnology sector, is making waves with its promising growth trajectory and innovative product offerings. With a market capitalization of $8.27..

Integer Holdings Corporation (ITGR) Stock Report: Analyst Consensus and Growth Potential

Integer Holdings Corporation (NYSE: ITGR) stands as a pivotal player in the healthcare sector, specifically within the medical devices industry. Headquartered in Plano, Texas, and with a market capitalization of..

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Unraveling the 140% Upside Potential

Soleno Therapeutics, Inc. (SLNO) is positioning itself as a significant player in the biotechnology sector with a focus on developing treatments for rare diseases. Headquartered in Redwood City, California, this..

TG Therapeutics, Inc. (TGTX) Stock Analysis: Strong Buy Ratings and 51.25% Upside Potential

TG Therapeutics, Inc. (NASDAQ: TGTX) stands out in the healthcare sector as a dynamic player in the biotechnology industry. With a market capitalization of $4.65 billion, the company has been..

Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations

Axsome Therapeutics, Inc. (NASDAQ: AXSM) stands as a compelling figure in the biotechnology sector, captivating investor attention with its impressive 63.20% revenue growth amidst the challenges of developing treatments for..

Glaukos Corporation (GKOS) Stock Analysis: A Promising 13.99% Upside in the Medical Devices Sector

Glaukos Corporation (NYSE: GKOS), a leader in the healthcare sector focused on ophthalmic pharmaceuticals and medical technology, is capturing investor attention with an enticing potential upside of 13.99%. As a..

Masimo Corporation (MASI) Stock Analysis: Exploring a 44% Upside Potential in the Healthcare Sector

Masimo Corporation (NASDAQ: MASI), a prominent player in the healthcare sector specializing in medical devices, offers an intriguing opportunity for investors seeking exposure to innovative patient monitoring technologies. Headquartered in..

Alkermes plc (ALKS) Stock Analysis: Unveiling a 55% Upside Potential for Investors

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector and a key figure in the specialty and generic drug manufacturing industry, presents a compelling investment opportunity with substantial..

Bausch + Lomb Corporation (BLCO): Investor Outlook on Growth Potential and Strategic Positioning

Bausch + Lomb Corporation (NYSE: BLCO) stands as a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $5.87 billion,..

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 10.44% Upside Potential

Ionis Pharmaceuticals, Inc. (IONS), a prominent player in the biotechnology sector, is making waves in the healthcare industry with its innovative RNA-targeted medicines. With a market capitalization of $12.9 billion,..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Potential 3.39% Upside in Biotech Innovation

Investors searching for opportunities in the biotechnology sector might find Akero Therapeutics, Inc. (NASDAQ: AKRO) an intriguing prospect. This South San Francisco-based company, with a market capitalization of $4.5 billion,..

Search

Funds

January 5, 2026

Global Opportunities Trust to appoint Goodhart as discretionary investment manager

Global Opportunities Trust plc has announced plans to appoint Goodhart Partners as discretionary investment manager, subject to regulatory approval...

Volta Finance appoints BNP Paribas Asset Management Europe as investment manager

Volta Finance Limited has appointed BNP Paribas Asset Management Europe as its new investment manager, effective 31 December 2025, following the merger of AXA Investment Managers and BNP Paribas Asset Management...

Outlook for investing in China 2026

Dale Nicholls, portfolio manager of Fidelity China Special Situations, outlines his outlook for Chinese equities in 2026, highlighting policy stabilisation, structural innovation leadership, and selective opportunities in advanced manufacturing, automation, and consumer sectors...

Global Opportunities Trust Appoints Juniper as an External AIFM

Goodhart Partners is set to become discretionary investment manager to Global Opportunities Trust plc, aiming to increase portfolio flexibility, risk management, and real return potential...

Real Estate Credit Investments: Why 95% of Investors Voted to Stay In While Rivals Wind Down (Video)

RECI is going against the tide — while many peers wind down, it secured 95% shareholder backing to continue. Ravi Stickney and Andreas Tautscher explain the strategic edge RECI holds in credit markets reshaped by higher rates and asset repricing...
Search

Funds

January 5, 2026

FTSE 100

Funds